CN108348611A - 使用pi3k抑制剂和mdm2抑制剂的联合疗法 - Google Patents

使用pi3k抑制剂和mdm2抑制剂的联合疗法 Download PDF

Info

Publication number
CN108348611A
CN108348611A CN201680063787.3A CN201680063787A CN108348611A CN 108348611 A CN108348611 A CN 108348611A CN 201680063787 A CN201680063787 A CN 201680063787A CN 108348611 A CN108348611 A CN 108348611A
Authority
CN
China
Prior art keywords
cancer
compound
pharmaceutical composition
inhibitor
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680063787.3A
Other languages
English (en)
Chinese (zh)
Inventor
G·卡波尼格罗
T·霍恩-斯皮隆
J·莱哈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN108348611A publication Critical patent/CN108348611A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680063787.3A 2015-08-28 2016-08-25 使用pi3k抑制剂和mdm2抑制剂的联合疗法 Pending CN108348611A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562211016P 2015-08-28 2015-08-28
US62/211,016 2015-08-28
PCT/IB2016/055075 WO2017037586A1 (en) 2015-08-28 2016-08-25 Combination therapy using pi3k inhbitor and mdm2 inhibitor

Publications (1)

Publication Number Publication Date
CN108348611A true CN108348611A (zh) 2018-07-31

Family

ID=56896742

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680063787.3A Pending CN108348611A (zh) 2015-08-28 2016-08-25 使用pi3k抑制剂和mdm2抑制剂的联合疗法

Country Status (5)

Country Link
US (1) US20180318275A1 (https=)
EP (1) EP3341023A1 (https=)
JP (1) JP2018528949A (https=)
CN (1) CN108348611A (https=)
WO (1) WO2017037586A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108486041A (zh) * 2018-03-28 2018-09-04 华南农业大学 PI3K/Akt信号通路在鸡胚成纤维细胞内对马立克氏病毒增殖的应用及其检测方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018001903A (es) * 2015-08-14 2018-06-20 Novartis Ag Inhibidores de mdm2 para el tratamiento de melanoma uveal.
CN111868039A (zh) * 2017-09-26 2020-10-30 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
CN114450008A (zh) * 2019-09-16 2022-05-06 诺华股份有限公司 Mdm2抑制剂用于治疗骨髓纤维化的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120129871A1 (en) * 2010-11-19 2012-05-24 Novartis Ag Crystalline form of an inhibitor of MDM2/4 and p53 interaction
WO2013111105A1 (en) * 2012-01-26 2013-08-01 Novartis Ag Imidazopyrrolidinone compounds
WO2015070224A2 (en) * 2013-11-11 2015-05-14 Amgen Inc. Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2015097622A1 (en) * 2013-12-23 2015-07-02 Novartis Ag Pharmaceutical combinations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120129871A1 (en) * 2010-11-19 2012-05-24 Novartis Ag Crystalline form of an inhibitor of MDM2/4 and p53 interaction
WO2013111105A1 (en) * 2012-01-26 2013-08-01 Novartis Ag Imidazopyrrolidinone compounds
WO2015070224A2 (en) * 2013-11-11 2015-05-14 Amgen Inc. Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2015097622A1 (en) * 2013-12-23 2015-07-02 Novartis Ag Pharmaceutical combinations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
郑杰: "《肿瘤的细胞和分子生物学》", 30 April 2014, 军事医学科学出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108486041A (zh) * 2018-03-28 2018-09-04 华南农业大学 PI3K/Akt信号通路在鸡胚成纤维细胞内对马立克氏病毒增殖的应用及其检测方法

Also Published As

Publication number Publication date
JP2018528949A (ja) 2018-10-04
US20180318275A1 (en) 2018-11-08
WO2017037586A1 (en) 2017-03-09
EP3341023A1 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
EP3340990B1 (en) Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
JP6320379B2 (ja) Ｃｄｋ４／６阻害剤およびｂ−ｒａｆ阻害剤の組合せ医薬
JP2019031500A (ja) 併用療法
KR20180041677A (ko) Mdm2 억제제 및 그의 조합물
KR20150141971A (ko) 이브루티닙 병용 요법
US20210186973A1 (en) Combination of ribociclib and dabrafenib for treating or preventing cancer
CN105338980A (zh) 药物组合
US10328066B2 (en) Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
CN114246864B (zh) Csf1r激酶抑制剂及其用途
CN108348611A (zh) 使用pi3k抑制剂和mdm2抑制剂的联合疗法
JP2018522936A (ja) ぶどう膜黒色腫の処置のためのｍｄｍ２阻害剤
TW202116301A (zh) 藥物組合及其用途
CN104661681B (zh) 包含磷脂酰肌醇3-激酶抑制剂和芳香酶抑制剂的药物组合
US10328065B2 (en) Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
TWI698238B (zh) Ｅｚｈ２抑制劑組合治療
CN107921026A (zh) 药物组合物包含(a)α‑同种型特异性PI3K抑制剂alpelisib(BYL719)和(b)AKT抑制剂,优选MK‑2206,afuresertib或uprosertib及其在治疗/预防癌症中的应用
CN108135905A (zh) 用于治疗癌症的cdk4/6抑制剂lee011、mek1/2抑制剂曲美替尼以及可任选还包括pi3k抑制剂byl719的组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180731